# Impact of BAFF Gene Polymorphisms on the Risk of Ulcerative Colitis and the Efficacy of Vedolizumab.

> **NCT07564895** · — · COMPLETED · sponsor: **Second Affiliated Hospital of Wenzhou Medical University** · enrollment: 841 (actual)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07564895
- **Lead sponsor:** Second Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 841 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07564895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07564895, "Impact of BAFF Gene Polymorphisms on the Risk of Ulcerative Colitis and the Efficacy of Vedolizumab.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07564895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*